Cost data were collected in five standard categories: personnel (clinical and support), recurrent goods (e.g., test kits), recurrent services (e.g., utilities), capital (e.g., computers and vehicles), and building or other operating space (purchase or rental).
The first-line treatment of patients with KIT-positive, unresectable, recurrent, and/or metastatic gastrointestinal stromal tumor (GIST) is the oral tyrosine kinase inhibitor (TKI) imatinib; however, half of the patients will have experienced disease progression after ∼20 months [ 1].
Pathological examination revealed that the tumors were composed of viable KIT-positive spindle cells, and the recurrent tumors were diagnosed as nilotinib-resistant GIST.
Recurrent goods utilised at the PMTCT centres included HIV test kits, nevirapine tablets and syrup, disposable surgical kits, disposable delivery kits, needles and syringes, gloves, sterillium, spirit, sodium hypochlorite solution, distilled water, test tubes, serum containers, droppers, micro-tips, cotton, filter paper, soap, stationery and some miscellaneous items.
To determine whether imatinib mesylate could be a potentially useful agent in the treatment of endometrial cancer, we assessed the expressions of Abl, c-Kit, and PDGFR in both primary and recurrent endometrial carcinoma.
Lastly, lenvatinib is a multi-kinase inhibitor (targets including VEGFR1 3, FGFR1 4, PDGFR-α, KIT, and RET) indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Specifically, Imatinib mesylate targets PDGF receptors while KIT was indicated as a mediator of anti-tumor activity in patients with recurrent GBM [ 29].
Several recurrent goods were not directly purchased by the PMTCT centres, for example, the HIV test kits, nevirapine tablets and nevirapine syrup were supplied to the PMTCT centres by APSACS.
102 Pazopanib, a TKI targeting VEGFR, PDGFR, and c-kit, has produced an ORR of 18% in a phase II trial with 36 recurrent EOC patients, including 9 with platinum-refractory and -resistant disease.
